As an example, an integrative epigenomic analysis performed in adult B-ALL provided the basis for a clinical trial with BCL6 inhibitors in specific cases of B-ALL with a concrete epigenetic alteration [138]. This evidence concerns the gene BCL6 and precursor B-cell acute lymphoblastic leukemia.